My ePortfolio Register   

CTL019 in adult patients with relapsed or refractory diffuse large B-cell Lymphoma

CTL019 consists of genetically engineered autologous T cells expressing a chimeric antigen receptor (CAR).

Results from a prior single-center phase 2 study at the University of Pennsylvania showed that a single infusion of CTL019 could produce durable remissions in adult patients with relapsed or refractory (r/r) diffuse large B-cell lymphoma (DLBCL).

The JULIET trial is a Novartis-sponsored, single-arm, open-label, multicenter, global phase 2 trial of CTL019 in adult patients with r/r DLBCL.

Patients in the JULIET trial had relapse or progression after at least 2 prior lines of therapy and were not candidates for stem cell transplant.

Cryopreserved leukapheresis products were used to manufacture CAR T cells, which were provided to patients at 27 centers in 10 countries on 4 continents.

The primary endpoint was centrally reviewed best overall response rate (ORR: complete response [CR] partial response [PR]).

85 patients received a single dose of CTL019. Among 51 patients with ≥3 months follow-up or earlier discontinuation, best ORR was 59% (43% achieved CR and 16% achieved PR).

The JULIET trial met its primary endpoint.

All patients in CR at 3 months remained in CR at data cutoff.

All-grade and grade 3 or 4 cytokine release syndrome (CRS) occurred in 57% and 26% of treated patients, respectively; no CRS-related deaths were reported.

21% and 13% of patients had all-grade and grade 3 or 4 neurologic events, respectively; no cases of cerebral edema were reported.

No deaths were attributed to CTL019.

This preplanned interim analysis of a global study of CTL019 in adults with r/r DLBCL is consistent with the high response rates and durable responses observed in the previous single-center experience.

Source: EHA

0

Comments

Please click on the 'New Comment' link to the left to add a new comment, or alternatively click any 'Add Comment' link next to any existing post to respond. The views expressed here are not those of ecancer. For more information please view our Privacy Policy.



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence